Influence of aetiology on the effects of treatment in heart failure

European Journal of Preventive Cardiology

Volumn 6, Issue 3, 1999, Pages 131-139

  Cleland, John G F ^a   Swedberg, Karl ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; NITRATE; WARFARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; DIGOXIN; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS;

EID: 0032768373     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748739900600302     Document Type: Article

References (87)

1. Cleland JGF, Erdmann E, Ferrari R, Hess OM, Wilson PA Poole, Remme WJ, et al Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741–751.
2. Garg R, Yusuf S. Epidemiology of congestive heart failure. In: Barnett DB, Pouler H, Francis GS (editors): Congestive cardiac failure – Pathophysiology and treatment. London: Marcel Dekker; 1993. pp. 9–25.
3. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565–1574.
4. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996; 156: 146–157.
5. Benton RE, Coughlin SS, Refft MC. Predictors of coronary angiography in patients with idiopathic dilated cardiomyopathy: the Washington, DC dilated cardiomyopathy study. J Clin Epidemiol 1994; 47: 501–511.
6. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels W, et al Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood institute Workshop). Am J Cardiol 1992; 69: 1458–1466.
7. Parameshwar J, Shackell MM, Richardson A, Wilson PA Poole, Sutton GC. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992; 42: 287–289.
8. Brookes CIO, Hart P, Keogh BE, Cleland JGF. Angiography and the aetiology of heart failure. Postgrad Med J 1995; 71: 480–482.
9. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–1178.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
11. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
12. Peart S, Brennan PJ, Broughton P, Dollery C, Hudson MF, Lever AF, et al Medical Research Council of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.
13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
14. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
15. Uretsky BF, Young JB, Shahidi E, Yellen LG, Harrison MC, Jolly K, on behalf of the PROVED investigator group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955–962.
16. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. New Engl J Med 1993; 329: 1–7.
17. Gheorghiade M, Young JB, Uretsky BF, Packer M: The effects of digoxin withdrawal in patients with stable heart failure due to coronary artery disease compared to primary cardiomyopathy; insights from the PROVED and RADIANCE studies [abstract]. Circulation 1995; 92: 1–142.
18. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 1997; 336: 525–533.
19. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992; 69: 103–107.
20. Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988; 62: 67A–72A.
21. Swedberg K, Heikkila U Idanpaan, Remes J, for the CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987; 316: 1429–1435.
22. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991; 325: 293–302.
23. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 1991; 326: 303–310.
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456.
25. Yusuf S, Nicklas JM, Timmis G, Breneman G, Jafri SM, Duvernoy WFC, et al Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992; 327: 685–691.
26. Doherty NEI, Seelos KC, Suzuki JI, Caputo GR, O'Sullivan M, Sobol SM, et al Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin converting enzyme inhibitor therapy in dilated cardiomyopathy. J Am Coll Cardiol 1992; 19: 1294–1302.
27. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Effect of antiplatelet agents on survival in patients with left ventricular systolic dysfunction [abstract]. Circulation 1995; 92 (suppl 1): 1-665–1-666.
28. Cleland JGF, Poole-Wilson PA. Is aspirin safe in heart failure?: more data. Heart 1996; 76: 426–427.
29. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, et al Is aspirin safe for patients with heart failure? Br Heart J 1995; 74: 215–219.
30. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997; 12: 276–287.
31. Kober L, Pedersen C Torp, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 1995; 333: 1670–1676.
32. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction – Results of the survival and ventricular enlargement trial. New Engl J Med 1992; 327: 669–677.
33. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 1997; 18: 41–51.
34. Brembilla-Perrot B, de la Chasse A. Terrier, Jacquemin L, Beurrier D, Houplon P. The signal-averaged electrocardiogram is of limited value in patients with bundle branch block and dilated cardiomyopathy in predicting inducible ventricular tachycardia or death. Am J Cardiol 1997; 79: 154–159.
35. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et alβ-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426–2441.
36. Bristow MR, Gilbert EM, Abraham WT, Adams KT, Fowler MB, Hershberger RE, et al for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–2816.
37. Waagstein F. Metoprolol in addition to ACE-inhibitors causes regression of left ventricular dilatation and increases exercise ejection fraction in ischaemic cardiomyopathy [abstract]. J Am Coll Cardiol 1997; 29: 206A.
38. Fisher ML, Gottlieb SS, Plotnick G, Greenberg NL, Patten RD, Bennett SK, et al Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23: 943–950.
39. Cleland JGF, Pennell DJ, Murray GD, Ray SG, Lahiri A, Coats AJS, et al The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS). Eur J Heart Failure 1999; 1: 191–196.
40. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–1446.
41. Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, et al A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–1773.
42. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al for the US carvedilol study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996; 334: 1349–1355.
43. Australia–New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–380.
44. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Failure 1999; 1: 41–45.
45. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J. Clinical effects of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind placebo-controlled, randomised trials. Circulation 1998; 98: 1184–1191.
46. Doughty RN, Rodgers A, Sharps N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure – a systematic overview of randomised controlled trials. Eur Heart J 1997; 18: 560–565.
47. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomised trials. J Am Coll Cardiol 1997; 30: 27–34.
48. Cleland JGF, Ray SG, McMurray JJV. Overview of post infarction trials. In: Cleland JGF (editor): Prevention Strategies after myocardial infarction. London: Science Press; 1994. pp 37–73.
49. McGowan J, Cleland JGF. Carvedilol in heart failure: clinical trials in progress. Heart Fail Rev 1999; (in press).
50. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. New Engl J Med 1986; 314: 1547–1552.
51. Doval HC, Nul DR, Grancelli HI, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–498.
52. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. New Engl J Med 1995; 333: 77–82.
53. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 2128–2134.
54. Nul DR, Grancelli HI, Varini SD, Soifer S, Scapin O, Perrone S, et al No ethiologic differences in survival benefits from amiodarone in severe congestive heart failure [abstract], J Am Coll Cardiol 1997; 29: 247A.
55. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al for the PRAISE Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996; 335: 1107–1114.
56. Cohn JN, Ziesche SM, Loss LE, Anderson GF and The V-HeFT study group. Effect of felodipine on short-term exercise and neurohormones and long-term mortality in heart failure: results of V-HeFT-III [abstract]. Circulation 1995; 92: 1–143.
57. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995; 73: 428–433.
58. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, et al Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996; 94: 346–352.
59. Liao YH. Interventional study of diltiazem in dilated cardiomyopathy: a report of multiple centre clinical trial in China. Chinese cooperative group of diltaizem intervention trial in dilated cardiomyopathy. Int J Cardiol 1998; 64: 25–30.
60. Richardson M, Cockburn N, Cleland JGF. Update of clinical trials in heart failure and myocardial infarction. Eur J Heart Failure 1999; 1: 109–115.
61. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S, Friday K, Lenkei S, et al Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52–60.
62. Hansen JF. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II -DAVIT II). Am J Cardiol 1990; 66: 779–785.
63. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251–269.
64. Aspirin Myocardial Infarction Study Research Group. A randomised, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661–668.
65. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure patients with coronary heart disease. J Cardiac Failure 1997; 3: 249–254.
66. Cowburn PJ, Cleland JGF. Risk stratification. In: Cleland JGF, Cowburn PJ, McMurray JJV (editors): Heart failure. A systematic approach for clinical practice. London: Science Press; 1997. pp. 33–48.
67. Mickleborough LL, Maruyama H, Takagi Y, Mohamed S, Sun Z, Ebisuzaki E. Results of revascularisation in patients with severe left ventricular dysfunction. Circulation 1995; 92 (suppl II): II-73–II-79.
68. Christakis GT, Weisel RD, Fremes SE, Ivanov J, David TE, Goldman BS, et al Coronary artery bypass grafting in patients with poor ventricular function. J Thorac Cardiovasc Surg 1992; 103: 1083–1092.
69. Milano CA, White WD, Smith LR, Jones RH, Lowe JE, Smith PK, et al Coronary artery bypass in patients with severely depressed ventricular function. Ann Thorac Surg 1993; 56: 487–493.
70. Langenburg SE, Buchanan SA, Blackbourne LH, Scheri RP, Sinclair KN, Martinez J, et al Predicting survival after coronary revascularisation for ischemic cardiomyopathy. Ann Thorac Surg 1995; 60: 1193–1197.
71. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983; 68: 785–795.
72. O'Connor CM, Puma JA, Gardner LH, Califf RC, Jones RH. A 25-year experience in patients (pts) with coronary artery disease (CAD) and chronic heart failure (CHF): outcomes with medical therapy and bypass surgery (CABG) [abstract]. J Am Coll Cardiol 1996; 27 (suppl A): 142A.
73. Cleland JGF. Clinical trials in stable and unstable angina. In: Cleland JGF (editor): Asymptomatic Coronary Artery Disease and Angina. London: Science Press; 1996. pp. 62–100.
74. Cleland JGF, Krikler D. Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J 1993; 69: 54–62.
75. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary heart disease – the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258–265.
76. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67–73.
77. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–2069.
78. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin–angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969–1973.
79. Andreotti F, Kluft C, Davies GJ, Huisman LGM, De-Bart ACW, Maseri A. Effect of propranolol (long acting) on the circadian fluctuation of tissue plasminogen activator and plasminogen activator inhibitor 1. Am J Cardiol 1991; 68: 1295–1299.
80. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Effect of warfarin anti-coagulation on survival in patients with left ventricular systolic dysfunction [abstract]. J Am Coll Cardiol 1996; 27 (suppl A): 142A.
81. Cleland JGF, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomised clinical trials. Eur Heart J 1996; 17: 674–681.
82. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, et al Effects of an inhibitor of HMG CoA reductase on serum lipoproteins and ubiquinone 10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981; 305: 478–482.
83. McMurray J, McLay J, Chopra M, Bridges A, Belch JJF. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 65: 1261–1262.
84. Hofman-Bang C, Rehnquist N, Swedberg K, Wiklund I, Astrom H, for the Q10 study group. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Cardiac Failure 1995; 1: 101–107.
85. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 4240–4244.
86. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q-10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. Clin Invest 1993; 71 (suppl):S134–S136.
87. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 65: 521–523.